Sunday 13 July 2014
Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer.
Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine.
Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth.
In August 2012, the U.S. Food and Drug Administration approved enzalutamide for the treatment of castration-resistant prostate cancer.